The world's first successful treatment of liver failure with human embryonic stem cell-derived hepatocytes

China News Service, Changsha, August 25 (Zhang Yinghonglei) The National Engineering Research Center for Human Stem Cells in Changsha, Hunan announced on the 25th, "The use of human embryonic stem cells to induce differentiation of hepatocytes is safe in the treatment of acute / acute-on-chronic liver failure.

China is a country with a large number of liver diseases, with more than 6 million new cases of end-stage liver disease every year.

Mr.

Lu Guangxiu, director of the National Engineering Research Center for Human Stem Cells, said that the cell preparations used for treatment are derived from human embryonic stem cells

Previous preclinical efficacy studies have demonstrated that liver cell preparations can significantly improve the survival rate of animal models of liver failure—compared to the control group’s survival rate of only 6.

Huang Yan, director of the Department of Infectious Diseases at Xiangya Hospital of Central South University, who is in charge of the clinical research, said that the project has been submitted to the National Health Commission of China for clinical research since June 2019.

Lingo, deputy director of the National Engineering Research Center for Human Stem Cells, said that the hepatocyte preparations used in this project were produced in accordance with the requirements of the "Good Manufacturing Practice (GMP)".

At present, there are no embryonic stem cell-related cell preparations on the market in the world

It is reported that the team of the National Engineering Research Center for Human Stem Cells successfully constructed the world's first human therapeutic cloned embryos in 1999, and established China's first human embryonic stem cell line in 2002.